Dr Rachel Livingstone

  • Honorary Clinical Lecturer (Institute of Cardiovascular & Medical Sciences)

email: Rachel.Livingstone@glasgow.ac.uk

Institute of Cardiovascular & Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, G12 8QQ

ORCID iDhttps://orcid.org/0000-0003-0950-5016

Publications

List by: Type | Date

Jump to: 2020 | 2018 | 2017 | 2015 | 2014
Number of items: 7.

2020

Livingstone, R. , Boyle, J.G. and Petrie, J.R. (2020) How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes? Diabetic Medicine, 37(4), pp. 513-521. (doi: 10.1111/dme.13911) (PMID:30697804)

2018

Boyle, J. G., Livingstone, R. and Petrie, J. R. (2018) Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clinical Science, 132(15), pp. 1699-1709. (doi: 10.1042/CS20171299) (PMID:30115742)

2017

Livingstone, R. , Boyle, J. G. and Petrie, J. R. (2017) A new perspective on metformin therapy in type 1 diabetes. Diabetologia, 60(9), pp. 1594-1600. (doi: 10.1007/s00125-017-4364-6) (PMID:28770327)

Laidlaw, K. M.E., Livingstone, R. , Al-Tobi, M. , Bryant, N. J. and Gould, G. W. (2017) SNARE phosphorylation: a control mechanism for insulin-stimulated glucose transport and other regulated exocytic events. Biochemical Society Transactions, 45(6), pp. 1271-1277. (doi: 10.1042/BST20170202) (PMID:29101310)

2015

Livingstone, R. and Boyle, J. (2015) Improving the quality of assessment and management of hypoglycaemia in hospitalised patients with diabetes mellitus by introducing 'hypo boxes' to general medical wards with a specialist interest in diabetes. BMJ Quality Improvement Reports, 4(1), u207686.w3. (doi: 10.1136/bmjquality.u207686.w3067)

Livingstone, R., Fisher, M. and McKay, G. (2015) Do we need another SGLT2 inhibitor? Practical Diabetes, 32(2), 47-48a. (doi: 10.1002/pdi.1920)

2014

Livingstone, R., Fisher, M. and McKay, G. (2014) Apixaban. Practical Diabetes, 31(6), 262-263a. (doi: 10.1002/pdi.1880)

This list was generated on Sat Nov 27 02:41:28 2021 GMT.
Jump to: Articles
Number of items: 7.

Articles

Livingstone, R. , Boyle, J.G. and Petrie, J.R. (2020) How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes? Diabetic Medicine, 37(4), pp. 513-521. (doi: 10.1111/dme.13911) (PMID:30697804)

Boyle, J. G., Livingstone, R. and Petrie, J. R. (2018) Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clinical Science, 132(15), pp. 1699-1709. (doi: 10.1042/CS20171299) (PMID:30115742)

Livingstone, R. , Boyle, J. G. and Petrie, J. R. (2017) A new perspective on metformin therapy in type 1 diabetes. Diabetologia, 60(9), pp. 1594-1600. (doi: 10.1007/s00125-017-4364-6) (PMID:28770327)

Laidlaw, K. M.E., Livingstone, R. , Al-Tobi, M. , Bryant, N. J. and Gould, G. W. (2017) SNARE phosphorylation: a control mechanism for insulin-stimulated glucose transport and other regulated exocytic events. Biochemical Society Transactions, 45(6), pp. 1271-1277. (doi: 10.1042/BST20170202) (PMID:29101310)

Livingstone, R. and Boyle, J. (2015) Improving the quality of assessment and management of hypoglycaemia in hospitalised patients with diabetes mellitus by introducing 'hypo boxes' to general medical wards with a specialist interest in diabetes. BMJ Quality Improvement Reports, 4(1), u207686.w3. (doi: 10.1136/bmjquality.u207686.w3067)

Livingstone, R., Fisher, M. and McKay, G. (2015) Do we need another SGLT2 inhibitor? Practical Diabetes, 32(2), 47-48a. (doi: 10.1002/pdi.1920)

Livingstone, R., Fisher, M. and McKay, G. (2014) Apixaban. Practical Diabetes, 31(6), 262-263a. (doi: 10.1002/pdi.1880)

This list was generated on Sat Nov 27 02:41:28 2021 GMT.